Contribution of machine learning to tumor growth inhibition modeling for hepatocellular carcinoma patients under Roblitinib (FGF401) drug treatment
Abstract Machine learning (ML) opens new perspectives in identifying predictive factors of efficacy among a large number of patients’ characteristics in oncology studies. The objective of this work was to combine ML with population pharmacokinetic/pharmacodynamic (PK/PD) modeling of tumor growth inh...
Main Authors: | Mélanie Wilbaux, David Demanse, Yi Gu, Astrid Jullion, Andrea Myers, Vasiliki Katsanou, Christophe Meille |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-08-01
|
Series: | CPT: Pharmacometrics & Systems Pharmacology |
Online Access: | https://doi.org/10.1002/psp4.12831 |
Similar Items
-
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
by: Stephen L. Chan, et al.
Published: (2022-06-01) -
The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
by: Brynjar Mauseth, et al.
Published: (2019-09-01) -
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
by: Hiroaki Kanzaki, et al.
Published: (2021-03-01) -
FGF19–<i>FGFR4</i> Signaling in Hepatocellular Carcinoma
by: Aroosha Raja, et al.
Published: (2019-06-01) -
FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention
by: Yijun Wang, et al.
Published: (2021-03-01)